PAVmed Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)0.72 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $2.70Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $26.6M Shares Outstanding 9.8M diluted Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary PAVmed Inc. has successfully completed a multi-year capital restructuring, eliminating legacy convertible debt overhangs and simplifying its capital structure to common stock and term debt. The company's primary value driver is its 15% equity stake and 25% voting interest in Lucid Diagnostics, which is seeing strong commercial momentum for its EsoGuard Esophageal DNA Test. With a clean balance sheet, a relaunched medical device portfolio under new leadership, and upcoming catalysts like potential Medicare coverage for EsoGuard and an FDA submission for the Veris implantable physiological monitor by the end of 2026, PAVmed represents a high-upside, diversified commercial life sciences play. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$16.00 Mean target$36.00 High · most bullish analyst$56.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $16.0015% Medicare coverage for EsoGuard is delayed or denied, limiting Lucid's revenue growth and preventing the exercise of Series D warrants. Veris Health faces regulatory delays with its FDA submission, and the company is forced to execute highly dilutive equity raises to fund operations as cash reserves dwindle. Base CaseCentral scenario $36.0060% Matches the consensus meanEsoGuard test volumes continue steady quarterly growth, and Medicare coverage progresses through standard regulatory timelines. Veris Health submits its implantable physiological monitor to the FDA by the end of 2026. The company maintains its cash runway into 2027 using pro forma cash reserves and selective capital raises, while slowly expanding its medical device pipeline. Bull CaseUpside scenario $56.0025% Lucid Diagnostics secures positive Medicare Local Coverage Determination (LCD) for EsoGuard, triggering $30 million in warrant exercises and accelerating commercial adoption. Concurrently, the Veris implantable physiological monitor receives FDA clearance ahead of schedule, and the relaunched medical device portfolio (including PortIO and Duke-licensed endoscopic imaging) signs high-value commercial partnerships. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |